 Rare disease specialists Millendo Therapeutics are hoping their drug livoletide will become the first treatment for Prader-Willi syndrome. Founder and CEO Julia Owens spoke to Paul Tunnah at JP Morgan about the challenges in orphan therapies and the companys rapid growth 